About
Therapeutics Targeting 12-Lipoxygenase
Areas of Focus
Categories
Small Molecule PharmaceuticalVirginia, DC, DE & Maryland
Team (22)
Adam Cuker
Director of the Penn Comprehensive Hemophilia & Thrombosis Program, Clinical Director, Penn Blood Disorders Center, Associate Professor of Medicine University of Pennsylvania
Veralox Therapeutics
team_member
Alex Martin
Chairman of the Board of Directors
Veralox Therapeutics
team_memberboard_chair
Alicia Herr
Associate Director, Program Management
Veralox Therapeutics
team_member
Ben Scruggs
Principal, Hatteras Venture Partners
Veralox Therapeutics
team_member
Christian Peters
Christian Peters, MD, PhD
Veralox Therapeutics
team_memberexecutive
Christopher Cavallaro
Director, Clinical Operations
Veralox Therapeutics
team_member
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
168
By Phase
PHASE2: 1PHASE1: 2
By Status
COMPLETED: 2RECRUITING: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT05785819Lead Sponsor
A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia
PHASE2Recruiting
60 participants
Started: Sep 26, 2023 · Completed: Mar 31, 2025
NCT05325346Lead Sponsor
A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects
PHASE1Completed
12 participants
Started: Mar 7, 2022 · Completed: Apr 14, 2022
NCT04783545Lead Sponsor
Phase I Study of VLX-1005 in Healthy Subjects
PHASE1Completed
96 participants
Started: Mar 24, 2021 · Completed: Jan 11, 2022
Locations (1)
Headquarters
Frederick, MD, United States
Map
Loading map...